News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Zogenix, Inc. and Mallinckrodt Inc., a Covidien plc (COV) Company, Enter Exclusive Co-Promotion Agreement for SUMAVEL(R) DosePro(R)


6/7/2012 9:21:59 AM

SAN DIEGO, June 7, 2012 (GLOBE NEWSWIRE) -- Zogenix Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, and Mallinckrodt LLC, the pharmaceuticals business of Covidien (NYSE:COV), today announced an exclusive co-promotion agreement for SUMAVEL DosePro (sumatriptan injection) Needle-free Delivery System in the United States.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES